The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
Competitors struggle, while MorphoSys investors see a path forward for pelabresib after all.
Rates of infection-related deaths continue to raise eyebrows, but the company has some potential explanations.
Daiichi aims to expand valemetostat into a new use, but Haihe Biopharma isn't far behind.
Dizal got a lucky break with golidocitinib, and now mid-stage data back the project’s activity in T-cell lymphoma.
But JNJ-75276617 still has much to prove.
Blueprint looks to a next-gen Ayvakit, while Cogent challenges with a molecule acquired from Daiichi Sankyo.